What Are the Classifications of Myelodysplastic Syndromes?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Myelodysplastic syndromes are generally classified into “lower risk MDS” and “higher risk MDS.” Your physician can tell you which classification you fall under based on the characteristics of your disease. The three primary characteristics are percent of marrow blasts (immature cells), chromosome abnormalities, and blood counts (platelets, red cells, and white cells). 

In general, if you have blasts that are less than 10 percent of total blood cells, you fall in the lower risk category. Blasts equal to or above 10 percent, many abnormal chromosomes, and low platelet and red and white blood cell counts put you in the higher risk category. 

The most commonly used classification system is called the International Prognostic Scoring System (IPSS). The table below shows how your risk category correlates to the IPSS score. A score of 0 to 1 is in the lower risk category, whereas a score above 1 places you in the higher risk category. 

 

IPSS Risk 

Score 

Average Survival 

Low 

5-6 years 

Intermediate 1 

0.5-1 

3-4 years 

Intermediate 2 

1.5-2 

1-1.5 years 

High 

= 2.5 

4-6 months 

 

These categories help determine the type of treatment you will receive. 

 

This content was last modified on August 11, 2007 .
Latest Cancer News
Neoadjuvant Chemotherapy for High-risk Localized Prostate Cancer Is Safe and Effective

March 19, 2010 — Neoadjuvant treatment with Taxotere® (docetaxel) and Emcyt® (estramustine) for high-risk localized prostate cancer appears to be safe and produces promising responses compared with standard treatment, according to the results of a Phase III randomized study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.

Type of Specialist Seen Affects Treatment Decisions for Men with Prostate Cancer

March 19, 2010 — Researchers from several U.S. medical centers have reported that “specialist visits relate strongly to prostate cancer treatment choices.” The details of this study were published in the March 8, 2010 issue of the Archives of Internal Medicine.

Tobacco Usage Affects Risk of Metastases of HPV-related Oropharynx Cancer

March 19, 2010 — Researchers from the University of Michigan have reported that current tobacco users with advanced, human papillomavirus (HPV)-positive oropharyngeal cancer are at increased risk of disease recurrence. The details of this study were published in the February 15, 2010 issue of Clinical Cancer Research.

Select news items provided by Reuters Health